CSF2 and rheumatoid arthritis: Notably, four out of the five reported cases, including ours, were associated with SASP treatment, suggesting a potential drug-specific trigger rather than a mere association with RA itself. Because SASP exhibits GM-CSF-suppressive effects and high tissue distribution in the lungs, its administration suppresses GM-CSF activity within the alveoli.